Tetrasubstituted purines as inhibitors of CDK1

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F03%3A00001584" target="_blank" >RIV/61989592:15310/03:00001584 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Tetrasubstituted purines as inhibitors of CDK1
Original language description
Cyclin-dependent kinases (CDKs) have raised considerable attention because of their pivotal role in the regulation of cell division cycle. Due to their hyperactivation in a number of transformed cells, drug discovery programs direct the effort towards the identification of chemical inhibitors of CDKs as anticancer agents. In our effort to enhance the affinity of purine inhibitors to CDKs, we introduced another side chain at C8. The straightforward syntheses of 2,6,8,9-tetrasubstituted purines [1-3] generally started from previously synthesised 2,6,9-trisubstituted purines [4,5] and are described in details (see Scheme 1). The inhibitor-CDK mutual interactions between CDK2 and inhibitor were subsequently verified by molecular modelling [6]. The introduced C8 substituents, however, lowered the CDK inhibitory activity, whereas the antiproliferative activity of several derivatives remained high (Tab. 1.).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
ED - Physiology
OECD FORD branch
—

Project
<a href="/en/project/GA301%2F02%2F0475" target="_blank" >GA301/02/0475: Purine inhibitors of cyclin-dependent kinases as anticancer and antimitotic compounds</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2003
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)